We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Shares of Par Pharmaceutical Cos. recovered slightly on Friday, a day after hitting their lowest point in five years following the specialty drug maker's announcement that it has to restate nine quarters of results.
With the acquisition of Targent Incorporated's oncology assets by Spectrum Pharmaceuticals Inc., Irvine, California, Targent announced that Patrick Maguire, MD, PhD, has resigned as Chief Executive
Officer and Director.
AVANIR Pharmaceuticals announced that it has signed an exclusive agreement with Healthcare Brands International (HBI) to develop and market AVANIR's docosanol 10% cream (docosanol) as a treatment for cold sores in the European Union, (with the exception of Denmark, Finland, Greece, Italy, and Sweden, all of which are covered by previous license grants from AVANIR) Russia and the Ukraine.
OctoPlus, the drug delivery and development company, announced that it has obtained full rights for the development of all applications of OP-145 through expansion of the license agreement.
Croatian generic drugmaker Pliva, at the centre of a bid battle, said on Friday U.S. regulators had given a green light to three of its drugs after problems were fixed at production facilities in Zagreb.
The FDA has granted tentative approval to the generic version of abacavir sulfate oral solution, an HIV/AIDS medication manufactured by India-based Aurobindo Pharma.
Merck is likely the "big winner" in the second quarter of 2006, having outperformed Wall Street's expectations, a financial analyst says. But the company faces some potentially dangerous challenges in 2007.
BioSeek, Inc., a leader in applying integrated human biology systems for developing new therapeutics, announced today that it has entered into a collaboration agreement with GlaxoSmithKline (GSK).